BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 26761344)

  • 1. Mepolizumab (Nucala) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jan; 58(1486):11-2. PubMed ID: 26761344
    [No Abstract]   [Full Text] [Related]  

  • 2. Benralizumab (Fasenra) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2018 Feb; 60(1541):33-35. PubMed ID: 29485975
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma.
    Lim HF; Nair P
    Expert Rev Respir Med; 2015 Apr; 9(2):135-42. PubMed ID: 25578680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reslizumab (Cinqair) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jun; 58(1497):81-2. PubMed ID: 27305070
    [No Abstract]   [Full Text] [Related]  

  • 5. Biological treatment is approved for severe eosinophilic asthma.
    Mayor S
    BMJ; 2016 Nov; 355():i6472. PubMed ID: 27908911
    [No Abstract]   [Full Text] [Related]  

  • 6. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
    Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
    Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.
    Basu A; Dalal A; Canonica GW; Forshag M; Yancey SW; Nagar S; Bell CF
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):121-131. PubMed ID: 28277854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.
    Strauss RA; Jawhari N
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):121-123. PubMed ID: 29684570
    [No Abstract]   [Full Text] [Related]  

  • 10. Mepolizumab: First Global Approval.
    Keating GM
    Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tezepelumab (Tezspire) for severe asthma.
    Med Lett Drugs Ther; 2022 Feb; 64(1644):25-26. PubMed ID: 35171894
    [No Abstract]   [Full Text] [Related]  

  • 12. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
    Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma.
    Lam J; Hay JW; Salcedo J; Kenyon NJ
    J Asthma; 2019 Aug; 56(8):872-881. PubMed ID: 30003833
    [No Abstract]   [Full Text] [Related]  

  • 14. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.
    Whittington MD; McQueen RB; Ollendorf DA; Tice JA; Chapman RH; Pearson SD; Campbell JD
    Ann Allergy Asthma Immunol; 2017 Feb; 118(2):220-225. PubMed ID: 27923549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers for severe eosinophilic asthma.
    Yancey SW; Keene ON; Albers FC; Ortega H; Bates S; Bleecker ER; Pavord I
    J Allergy Clin Immunol; 2017 Dec; 140(6):1509-1518. PubMed ID: 29221581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mepolizumab use: Post-approval academic practice experience.
    Benjamin MR; Bochner BS; Peters AT
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):126-128. PubMed ID: 29653234
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab.
    Kurosawa M; Sutoh E
    Ann Allergy Asthma Immunol; 2019 Apr; 122(4):431-433. PubMed ID: 30578859
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults.
    Kallur L; Gonzalez-Estrada A; Eidelman F; Dimov V
    Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1275-1280. PubMed ID: 29157020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma.
    Shimoda T; Odajima H; Okamasa A; Kawase M; Komatsubara M; Mayer B; Yancey S; Ortega H
    Allergol Int; 2017 Jul; 66(3):445-451. PubMed ID: 28110896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies.
    Albers FC; Price RG; Smith SG; Yancey SW
    J Allergy Clin Immunol; 2017 Nov; 140(5):1464-1466.e4. PubMed ID: 28687231
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.